Maternal Serum Screening, Integrated, Specimen #1
0081062
Ordering Recommendation
Screening test for DS, T18, and ONTD. Risks determined using a combination of 1st and 2nd trimester serum markers, with or without 1st trimester nuchal translucency (NT) measurement. Results require a second sample between 15 and 24 weeks gestation (Maternal Serum Screening, Integrated, Specimen #2 0081064).
Mnemonic
MS INT-1
Methodology
Quantitative Chemiluminescent Immunoassay
Performed
Sun-Sat
Reported
2-4 days  
New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
The nuchal translucency (NT) measurement is preferred; however, the Integrated Maternal Screen can be interpreted with or without a NT measurement.  If performed, the NT measurement must be obtained between 10 weeks, 3 days and 13 weeks, 6 days gestation (Crown-Rump length (CRL) must be 3.6-8.5 cm). The NT measurement must also be performed by an ultrasonographer that is certified by one of the following agencies: Fetal Medicine Foundation (FMF) or Nuchal Translucency Quality Review (NTQR).  To avoid possible test delays for an ultrasonographer that is new to our database, please contact the genetic counselor at (800) 242-2787 extension 2141 prior to sending specimen.

Serum-only specimens may be drawn between 10 weeks, 0 days and 13 weeks, 6 days gestation. Crown-Rump length (CRL) must be 3.2-8.5 cm. The specimen collection and ultrasound date may be different.  
Collect
Serum separator tube or plain red.  
Specimen Preparation
Separate serum from cells ASAP or within 2 hours of collection. Transfer 0.5 mL serum to an ARUP Standard Transport Tube. (Min: 0.3 mL)  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Plasma. Specimens exposed to repeated freeze/thaw cycles. Hemolyzed specimens.  
Remarks
This test also requires the following information: The patient's date of birth, current weight, number of fetuses present, patient's race, if the patient requires insulin, if there is a known family history of neural tube defects, if the patient has had a previous pregnancy with a chromosome abnormality, if the patient is taking valproic acid or carbamazepine (Tegretol®), physician's name and phone number, For in vitro fertilization pregnancies, include the age of the egg donor at donation.

In addition to the above:


If a NT measurement is performed:
the date of ultrasound, the CRL measurement, the NT measurement and the name and certification number of the sonographer is required.
or

If no NT measurement is performed:
a due date or CRL measurement with the date of ultrasound is required.  
Stability
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 30 days  
Reference Interval
By report  
Interpretive Data
The first specimen of an Integrated Maternal Serum Screening is used to measure PAPP-A. Final interpretative report will be available when the second specimen test results are complete.  
Note
 
CPT Code(s)
84163
Components
Component Test Code*Component Chart NameLOINC
0080241Estimated Due Date11778-8
0080917Maternal Weight29463-7
0080920Maternal Screen Interpretation49586-1
0080926Maternal Race21484-1
0080927Number of Fetuses11878-6
0080932Maternal Age At Delivery21612-7
0080938Gestational Age (Exact)18185-9
0081065Nuchal Translucency (NT)12146-7
0081066Crown Rump Length11957-8
0081067Patient's PAPP-A32046-5
0081068MoM for PAPP-A32123-2
0081069Sonographer Certification #49089-6
0081070Sonographer Name49088-8
0081071Ultrasound Date34970-4
0081074MoM for NT49035-9
0081158Family History of Aneuploidy32435-0
0081331Best date to draw sample #2 by61100-4
2002854EER Maternal Screening, INT-1 
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • First trimester screen